{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:44:38Z","timestamp":1793342678636,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04454-8","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:58:14Z","timestamp":1752832694000},"page":"769-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Which topical ophthalmic drugs work best for Keratoconjunctivitis Sicca? A systematic review and meta-analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"key":"4454_CR1","doi-asserted-by":"publisher","unstructured":"Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI (2015) Prospective randomized trial comparing efficacy of topical Loteprednol Etabonate 0.5% versus Cyclosporine-A 0.05% for treatment of dry eye syndrome following hematopoietic stem cell transplantation, (in eng). Cornea 34(7):725\u2013732. https:\/\/doi.org\/10.1097\/ICO.0000000000000436","DOI":"10.1097\/ICO.0000000000000436"},{"key":"4454_CR2","doi-asserted-by":"publisher","unstructured":"Bron AJ et al. (2017) TFOS DEWS II pathophysiology report, (in eng), The Ocular Surface 15(3):438\u2013510. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.011","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"4454_CR3","doi-asserted-by":"publisher","unstructured":"Chen M et al. (2010) A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial,. (in eng). J Ocular Pharmacol Therapeut: The Official J Assoc Ocular Pharmacol Therapeut 26(4):361\u2013366. https:\/\/doi.org\/10.1089\/jop.2009.0145","DOI":"10.1089\/jop.2009.0145"},{"key":"4454_CR4","doi-asserted-by":"publisher","unstructured":"Comstock TL, Sheppard JD (2018) Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid, (in eng). Expert Opinion Pharmacothe 19(4):337\u2013353. https:\/\/doi.org\/10.1080\/14656566.2018.1439920","DOI":"10.1080\/14656566.2018.1439920"},{"key":"4454_CR5","doi-asserted-by":"crossref","unstructured":"Craig JP et al. TFOS DEWS II definition and classification report. The ocular surface 15(3):276\u2013283, 2017 2017. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1542012417301192","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"4454_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ajo.2019.01.026","volume":"202","author":"R Dana","year":"2019","unstructured":"Dana R et al (2019) Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age united states health care system, (in eng). Am J Ophthalmol 202:47\u201354. https:\/\/doi.org\/10.1016\/j.ajo.2019.01.026","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"4454_CR7","doi-asserted-by":"publisher","first-page":"e54028","DOI":"10.7759\/cureus.54028","volume":"16","author":"N Deo","year":"2024","unstructured":"Deo N, Nagrale P (2024) Dry eye disease: An overview of its risk factors, diagnosis, and prevalence by age, sex, and race, (in eng). Cureus 16(2):e54028. https:\/\/doi.org\/10.7759\/cureus.54028","journal-title":"Cureus"},{"key":"4454_CR8","doi-asserted-by":"publisher","unstructured":"Eom Y, Yoon KC, Kim HK, Song JS, Hyon JY, Kim HM (2023) A multicenter, randomized, double-blind evaluation of the efficacy of TJO-087 versus 0.05% cyclosporine A in moderate to severe dry eye. J Ocular Pharmacol Therapeut 39(1):27\u201335. https:\/\/doi.org\/10.1089\/jop.2022.0119","DOI":"10.1089\/jop.2022.0119"},{"key":"4454_CR9","doi-asserted-by":"publisher","unstructured":"Gao D, Da Z, Yang K, Shi Y (2022) Comparison of seven cyclosporine A formulations for dry eye disease: A systematic review and network meta-analysis. Front Pharmacol 13:882803. https:\/\/doi.org\/10.3389\/fphar.2022.882803","DOI":"10.3389\/fphar.2022.882803"},{"key":"4454_CR10","doi-asserted-by":"publisher","unstructured":"Jain AK, Sukhija J, Dwedi S, Sood A (2007) Effect of topical cyclosporine on tear functions in tear-deficient dry eyes, (in eng). Annals Ophthalmol (Skokie, Ill.) 39(1):19\u201325. https:\/\/doi.org\/10.1007\/BF02697322","DOI":"10.1007\/BF02697322"},{"key":"4454_CR11","doi-asserted-by":"publisher","unstructured":"Ji YW et al. (2019) Changes in human tear proteome following topical treatment of dry eye disease: Cyclosporine A versus Diquafosol Tetrasodium, (in eng), Investig Ophthalmol Visual Sci 60(15):5035\u20135044. https:\/\/doi.org\/10.1167\/iovs.19-27872","DOI":"10.1167\/iovs.19-27872"},{"key":"4454_CR12","doi-asserted-by":"publisher","unstructured":"Kim EC, Choi J-S, Joo C-K (2009) A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome, (in eng). Am J Ophthalmol 147(2):206\u2013213.e3. https:\/\/doi.org\/10.1016\/j.ajo.2008.08.015","DOI":"10.1016\/j.ajo.2008.08.015"},{"key":"4454_CR13","doi-asserted-by":"publisher","unstructured":"Leonardi A et al. (2016) Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial, (in eng). Eur J Ophthalmol 26(4):287\u2013296. https:\/\/doi.org\/10.5301\/ejo.5000779","DOI":"10.5301\/ejo.5000779"},{"key":"4454_CR14","doi-asserted-by":"publisher","unstructured":"Lin T, Gong L (2015) Topical fluorometholone treatment for ocular dryness in patients with Sj\u00f6gren syndrome: a randomized clinical trial in China, (in eng). Medicine 94(7):e551. https:\/\/doi.org\/10.1097\/MD.0000000000000551","DOI":"10.1097\/MD.0000000000000551"},{"key":"4454_CR15","doi-asserted-by":"publisher","unstructured":"Liu S, Yang G, Li Q, Tang S (2023) Safety and efficacy of topical diquafosol for the treatment of dry eye disease: An updated meta-analysis of randomized controlled trials. Indian J Ophthalmol 71(4):1304\u20131315. https:\/\/doi.org\/10.4103\/IJO.IJO_268_23","DOI":"10.4103\/IJO.IJO_268_23"},{"key":"4454_CR16","doi-asserted-by":"publisher","unstructured":"Liu S-H et al. (2022) Topical corticosteroids for dry eye. The Cochrane Database System Rev 2022(10):CD015070. https:\/\/doi.org\/10.1002\/14651858.CD015070.pub2","DOI":"10.1002\/14651858.CD015070.pub2"},{"key":"4454_CR17","doi-asserted-by":"publisher","unstructured":"Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease, (in eng), Dtsch Arztebl Int 112(5):71\u201381; quiz 82. https:\/\/doi.org\/10.3238\/arztebl.2015.0071","DOI":"10.3238\/arztebl.2015.0071"},{"key":"4454_CR18","doi-asserted-by":"publisher","unstructured":"Moawad P, Shamma R, Hassanein D, Ragab G, OEl Zawahry O (2022) Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome, (in en). Eur J Ophthalmol 32(1):673\u2013679. https:\/\/doi.org\/10.1177\/1120672121992680","DOI":"10.1177\/1120672121992680"},{"key":"4454_CR19","doi-asserted-by":"publisher","unstructured":"Nguyen A, Kolluru A, Beglarian T (2023) Dry eye disease: A review of anti-inflammatory therapies, (in eng). Taiwan J Ophthalmol 13(1):3\u201312. https:\/\/doi.org\/10.4103\/2211-5056.369606","DOI":"10.4103\/2211-5056.369606"},{"key":"4454_CR20","unstructured":"Page MJ et al. (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Intl J Surg 88:105906. [Online]. Available: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1743919121000406"},{"key":"4454_CR21","doi-asserted-by":"publisher","unstructured":"Park CH et al. (2019) Efficacy of topical cyclosporine nanoemulsion 0.05% compared with topical cyclosporine emulsion 0.05% and Diquafosol 3% in Dry Eye, (in eng). Korean J Ophthalmol: KJO 33(4):343\u2013352. https:\/\/doi.org\/10.3341\/kjo.2018.0116","DOI":"10.3341\/kjo.2018.0116"},{"key":"4454_CR22","doi-asserted-by":"publisher","unstructured":"Rao SN (2010) Topical cyclosporine 0.05% for the prevention of dry eye disease progression, (in eng). J Ocular Pharmacol Therapeut: The Official J Assoc Ocular Pharmacol Therapeut 26(2):157\u2013164. https:\/\/doi.org\/10.1089\/jop.2009.0091","DOI":"10.1089\/jop.2009.0091"},{"key":"4454_CR23","doi-asserted-by":"publisher","unstructured":"Roberts CW, Carniglia PE, Brazzo BG (2007) Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye, (in eng), Cornea 26(7):805\u2013809. https:\/\/doi.org\/10.1097\/ICO.0b013e318074e460","DOI":"10.1097\/ICO.0b013e318074e460"},{"key":"4454_CR24","doi-asserted-by":"publisher","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group, (in eng). Ophthalmology 107(4):631\u2013639. https:\/\/doi.org\/10.1016\/s0161-6420(99)00176-1","DOI":"10.1016\/s0161-6420(99)00176-1"},{"key":"4454_CR25","doi-asserted-by":"publisher","unstructured":"Shen Lee B, Kabat AG, Bacharach J, Karpecki P, Luchs J (2020) Managing dry eye disease and facilitating realistic patient expectations: A review and appraisal of current therapies, (in eng). Clin Ophthalmol 14:119\u2013126. https:\/\/doi.org\/10.2147\/opth.S228838","DOI":"10.2147\/opth.S228838"},{"key":"4454_CR26","doi-asserted-by":"publisher","unstructured":"Sheppard JD et al. (2014) Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%,\" (in eng). Eye Contact Lens 40(5):289\u2013296. https:\/\/doi.org\/10.1097\/ICL.0000000000000049","DOI":"10.1097\/ICL.0000000000000049"},{"key":"4454_CR27","doi-asserted-by":"publisher","unstructured":"Sheppard JD et al. (2021) A Water-free 0.1% cyclosporine a solution for treatment of dry eye disease: Results of the randomized phase 2B\/3 ESSENCE study, (in eng). Cornea 40(10):1290\u20131297. https:\/\/doi.org\/10.1097\/ICO.0000000000002633","DOI":"10.1097\/ICO.0000000000002633"},{"key":"4454_CR28","doi-asserted-by":"publisher","unstructured":"Singla S, Sarkar L, Joshi M (2019) Comparison of topical cyclosporine alone and topical loteprednol with cyclosporine in moderate dry eye in Indian population: A prospective study. Taiwan J Ophthalmol 9(3):173\u2013178. https:\/\/doi.org\/10.4103\/tjo.tjo_15_18","DOI":"10.4103\/tjo.tjo_15_18"},{"key":"4454_CR29","doi-asserted-by":"publisher","unstructured":"Sun X, Liu L, Liu C (2023) Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials, (in en). Graefe's Archive Clin Exp Ophthalmol 261(12):3355\u20133367. https:\/\/doi.org\/10.1007\/s00417-023-06083-4","DOI":"10.1007\/s00417-023-06083-4"},{"key":"4454_CR30","doi-asserted-by":"publisher","unstructured":"Zhu X, Li S, Wang M, Yao W, Huang X, Zhao L (2024) Effects of topical 0.05% Cyclosporine A on dry eye symptoms and parameters following small incision lenticule extraction. J Refract Surg 40(4):e229-e238. https:\/\/doi.org\/10.3928\/1081597X-20240311-03","DOI":"10.3928\/1081597X-20240311-03"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04454-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04454-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04454-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:57:25Z","timestamp":1770789445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04454-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4454"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04454-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No stated funding sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial disclosure"}},{"value":"Not applicable. This study does not involve human participants, human data or human tissue.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not involve individual data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}